Buccal Drug Delivery System Market Size Worth $6.31 Billion By 2030|
Buccal Drug Delivery System Market Size Worth $6.31 Billion By 2030| CAGR: 9.6%

Buccal Drug Delivery System Market Size Worth $6.31 Billion By 2030| CAGR: 9.6%

Overview

According to the research report, the global buccal drug delivery system market size was valued at USD 2.86 billion in 2021 and is expected to reach USD 6.31 Billion By 2030, growing at a CAGR of 9.6% during the forecast period.

The buccal drug delivery system includes managing the wanted drug through the buccal mucosal membrane lining of the oral cavity. This pathway is functional for mucosal and transmucosal drug administration. In the initial case, the objective is to obtain a release of the drug that is site-specific on the mucosa. In contrast, the subsequent case includes drug assimilation through the mucosal barrier to reach the systematic circulation. As the drug content within the buccal formulations can be a great deal lesser than capsules and tablets, toxicity or unbidden side effects will probably be lessened.

There are two percolation tracks for passive drug transport. They are paracellular and transcellular routes. Permeants can utilize two courses together. However, one way is generally favored over the other based on the physicochemical properties of the diffusion. As the intercellular spaces and cytoplasm are hydrophilic, lipophilic compounds would have solubilities in the environment that are low. But the cell membrane is relatively lipophilic, and hydrophilic solutes may encounter problems permeating through the cell membrane because the partition coefficient is low.

Request Sample Copy of Research Report @ https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market/request-for-sample

(The sample of this report is readily available on request. The report sample contains a brief introduction to the research report, Table of Contents, Graphical introduction of regional analysis, Top players in the market with their revenue analysis and our research methodology.)

Drivers

  • Increasing R&D activities fuel the growth of the buccal drug delivery market

The buccal drug delivery system market is encountering several growth opportunities in the time to come. These growth opportunities in the market are feasible with growing R&D activities in the field. A momentary treatment arrangement and availability of high application of these systems at the site of the target are also helping crucial factors to enhance revenues of growth in the global market.

Buccal drug delivery system is also witnessing detectable growth opportunities due to continual research. Buccal delivery has been known as the most favored and appropriate choice as juxtaposed to the dosage in oral form. These systems are accepted among the elderly population globally. This pathway of drug delivery ensures the discarding of the first-pass metabolism.

Inquire more about this report before purchase @ https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market/inquire-before-buying

(Inquire a report quote OR available discount offers to the sales team before purchase.)

Regional analysis

  • Significant investments by different market players in the North American region

The North American region is expected to share a position dominating the market revenue. The regional dominance is credited to the existence of several market players, enhanced diagnosis and treatment rates, and qualitative research to recognize appropriate drug candidates. Further, the significant investment by several market players to enhance the investment quality of new formulations is causing market growth. Favorable remuneration policies and escalated acquisition of these systems also represent crucial factors to improve the impetus of change in the regional market.

Key segmentation

  • By type analysis

Ease of formulation is a prime factor for the increase in demand for buccal tablets and lozenges

Depending on the type, the buccal tablets and lozenges captured the most significant share owing to growing consumer acceptance, cost-effectiveness, ease of formulation, and broad obtainability of drug contenders for formulation are components accountable for the growth of the segment.

  • By application analysis

To lessen the smoking and nicotine addiction, buccal drug delivery is preferred

The smoking cessation segment is considered the most significant share as buccal drug delivery is the most favored and impactful formulation for curing patients with smoking and nicotine addiction. Nicotine lozenges are more potent in distributing a high concentration of drugs than gums and alternative storage forms.

Request Customized Copy of Report @ https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market/request-for-customization

(We customize your report according to your research need. Ask our sales team for report customization.)

Covid-19 impact

Despite the surging R&D activity amidst the market players, a sharp decline in revenue and sales acquisition to the surge of the covid-19 pandemic. Apart from covid-19 medications, many other drug markets were majorly impacted, expediting the dip in the market for buccal drug delivery.

Key players

Applied Pharma Research, ARDEA BIOSCIENCES LIMITED, ARx LLC, AstraZeneca, Bayer AG, BioDelivery Sciences International, Inc., Catalent, Cynapsus Therapeutics Inc., Dr. Reddy’s Laboratories Ltd, Endo Pharmaceuticals plc, F. Hoffmann-La Roche Ltd, Generex Biotechnology, GlaxoSmithKline plc, Indivior PLC, MedLab, NAPP PHARMACEUTICALS LIMITED, Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi, Takeda Pharmaceutical Company Limited., and Teva Pharmaceutical Industries Ltd are some of the major players in the buccal drug delivery system market.

Recent developments

In July 2021, Johnson & Johnson acquired FDA approval for DARZALEX, a subcutaneous formulation that lessens the treatment time for multifold myeloma symptoms.

In December 2020, Pfizer Inc. gained FDA approval from BRAFTOVI in addition to the merger with cetuximab for the cure of patients with brafv600e-mutant metastatic colorectal cancer that have experienced prior therapy.

Browse detail report with in-depth TOC @ https://www.polarismarketresearch.com/industry-analysis/buccal-drug-delivery-system-market

Buccal drug delivery system market: By type

  • Sublingual Films
  • Buccal Tablets and Lozenges
  • Oral Sprays

Buccal drug delivery system market: By application

  • Pain Management
  • Smoking Cessation
  • Angina Pectoris
  • Others

Buccal drug delivery system market: By end use

  • Hospitals
  • Ambulatory Centers
  • Others

About Us:

Polaris Market Research is a worldwide market research and consulting organization. We give unmatched nature of offering to our customers present all around the globe across industry verticals. Polaris Market Research has expertise in giving deep-dive market insight along with market intelligence to our customers spread crosswise over various undertakings. We at Polaris are obliged to serve our different client base present over the enterprises of medicinal services, healthcare, innovation, next-gen technologies, semi-conductors, chemicals, automotive, and aerospace & defense, among different ventures present globally.

Contact Us:

Polaris Market Research

30 Wall Street

8th Floor,

New York City, NY 10005,

United States

Email: sales@polarismarketresearch.com

Web: https://www.polarismarketresearch.com

Ph: +1-929 297-9727

Leave a Reply

Your email address will not be published.